DrugPatentWatch Database Preview
Cumberland Pharms Company Profile
What is the competitive landscape for CUMBERLAND PHARMS, and what generic alternatives to CUMBERLAND PHARMS drugs are available?
CUMBERLAND PHARMS has six approved drugs.
There are twenty-seven US patents protecting CUMBERLAND PHARMS drugs.
There are two hundred and eight patent family members on CUMBERLAND PHARMS drugs in forty countries and fourteen supplementary protection certificates in thirteen countries.
Summary for Cumberland Pharms
| International Patents: | 208 |
| US Patents: | 27 |
| Tradenames: | 7 |
| Ingredients: | 6 |
| NDAs: | 6 |
Drugs and US Patents for Cumberland Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cumberland Pharms | VIBATIV | telavancin hydrochloride | POWDER;INTRAVENOUS | 022110-002 | Sep 11, 2009 | RX | Yes | Yes | 7,700,550 | See Pricing | See Pricing | ||||
| Cumberland Pharms | LACTULOSE | lactulose | FOR SOLUTION;ORAL | 074712-002 | Dec 10, 1997 | RX | No | Yes | See Pricing | See Pricing | |||||
| Cumberland Pharms | CALDOLOR | ibuprofen | SOLUTION;INTRAVENOUS | 022348-002 | Jun 11, 2009 | RX | Yes | Yes | 9,138,404 | See Pricing | See Pricing | ||||
| Cumberland Pharms | VIBATIV | telavancin hydrochloride | POWDER;INTRAVENOUS | 022110-001 | Sep 11, 2009 | DISCN | Yes | No | 7,351,691 | See Pricing | Y | Y | See Pricing | ||
| Cumberland Pharms | CALDOLOR | ibuprofen | SOLUTION;INTRAVENOUS | 022348-002 | Jun 11, 2009 | RX | Yes | Yes | 8,735,452 | See Pricing | See Pricing | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for CUMBERLAND PHARMS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Injection | 200 mg/mL, 30 mL vials | ➤ Subscribe | 2012-04-04 |
International Patents for Cumberland Pharms Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Australia | 2011281035 | See Pricing |
| South Korea | 101166250 | See Pricing |
| Spain | 2311014 | See Pricing |
| Japan | 2744527 | See Pricing |
| Canada | 2713965 | See Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Cumberland Pharms Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1292612 | 91908 | Luxembourg | See Pricing | 91908, EXPIRES: 20260501 |
| 1292612 | C 2012 002 | Romania | See Pricing | PRODUCT NAME: TELAVANCIN SAU O SARE ACCEPTABILA FARMACEUTIC A ACESTUIAINCLUZAND CLORHIDRAT DE TELAVANCIN; NATIONAL AUTHORISATION NUMBER: RO EU/1/11/705/001, RO EU/1/11/705/002; DATE OF NATIONAL AUTHORISATION: 20110902; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/11/705/001, EU/1/11/705/002; DATE OF FIRST AUTHORISATION IN EEA: 20110902 |
| 1292612 | 417 | Finland | See Pricing | |
| 1292612 | 2011C/045 | Belgium | See Pricing | PRODUCT NAME: VIBATIV - TELAVANCINE; AUTHORISATION NUMBER AND DATE: EU/1/11/705-001 20110902 |
| 1292612 | PA2012002 | Lithuania | See Pricing | PRODUCT NAME: TELAVANCINUM; REGISTRATION NO/DATE: EU/1/11/705/001, 2011 09 02 EU/1/11/705/002 20110902 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
